Renal disease is a major complication in patients following myeloablative allogeneic hematopoietic cell transplantation (HCT). Post-HCT patients receive immunosuppressive regimens containing calcineurin inhibitor (CNIs), cyclosporine or tacrolimus, for graft-versus-host disease prophylaxis. In this retrospective trial, we investigated pharmacogenomic associations in the multidrug resistance (ABCB1) and cytochrome P450 3A5 (CYP3A5) genes and acute kidney injury (AKI) and chronic kidney disease (CKD) in a cohort of 121 patients. ABCB1 and CYP3A5 are responsible for the renal disposition of CNIs, which are known to be nephrotoxic. AKI was defined as doubling of baseline serum creatinine during the first 100 days post-HCT, and CKD as at least one glomerular filtration rate o60 ml/min/m 2 between 6 and 18 months post-HCT. Patients were genotyped for CYP3A5*14*3 and ABCB1 single nucleotide polymorphisms (SNPs) (1199G4A, 1236C4T, 2677G4T/A and 3435C4T). Odds ratios were calculated using logistic regression. Haplotype estimation and univariate association analyses were performed because of strong ABCB1 linkage disequilibrium (LD). AKI occurred in 48 of 121 patients (39.7%) and CKD in 16 of 66 patients (24.2%) . No pharmacogenomic associations were found between ABCB1 and CYP3A5 SNPs and the incidences of AKI or CKD. The degree of LD(r Introduction Allogeneic hematopoietic cell transplantation (HCT) following myeloablative conditioning regimens is a mainstay in the treatment of hematologic malignancies. However, patient survival is limited by regimen-related toxicities. 1 Renal disease is a major complication post-HCT with acute kidney injury (AKI) and chronic kidney disease (CKD) significantly contributing to nonrelapse mortality in these patients. 2, 3 The genesis of renal disease after myeloablative allogeneic HCT is multifactorial and the identification of risk factors for both AKI and CKD is critical to allow for preventive measures. We have identified previously several risk factors including sinusoidal obstruction syndrome (SOS), amphotericin use and baseline serum creatinine. 2 Allogeneic HCT recipients routinely receive immunosuppressive regimens containing calcineurin inhibitors (CNIs), cyclosporine or tacrolimus, to prevent graft-versushost disease (GVHD). Cyclosporine trough concentrations 4400 ng/ml are associated with a higher incidence of renal injury. 4 It is important to note that cyclosporine-induced renal injury can occur despite low or normal concentrations of cyclosporine and may be complicated by patients' genetic susceptibility, concurrent use of other nephrotoxic drugs or disease-related factors.
We recently reported that plasma cyclosporine levels were not found to be associated with AKI in a cohort of patients undergoing myeloablative HCT.
2 Therefore, we hypothesized that the intracellular concentrations of CNIs within kidney tubular cells may be more predictive of the incidence of renal injury in these patients. CNI exposure in the kidney tubular cells is primarily mediated by the drugmetabolizing enzyme cytochrome P450 3A5 (CYP3A5) and the drug transporter P-glycoprotein (P-gp), which is encoded by the mutidrug resistance gene (ABCB1, also known as MDR1). [5] [6] [7] Genetic variability in the CYP3A5 and ABCB1 genes may alter the metabolism and transport of CNIs in renal tubular cells and may be an important risk factor for AKI and CKD post-HCT. 8, 9 Our goal was to evaluate the pharmacogenomic associations between the CYP3A5 and ABCB1 genotypes and the risk of CNI-induced renal injury in a retrospective study in our cohort of HCT patients. In CYP3A5, we focused on the CYP3A5*3 splice variant that leads to a truncated protein and loss of expression. 8 In ABCB1, we focused on four important single nucleotide polymorphisms (SNPs) that have been shown to be associated with changes in expression and activity of P-gp. 9 We investigated two synonymous ABCB1 SNPs that do not change an amino acid in the protein (1236C4T and 3435C4T). We also evaluated two nonsynonymous SNPs; the tri-allelic non-synonymous SNP at nucleotide position 2677, which results in a 2677G4T (Ala893Ser) or a 2677G4A (Ala893Thr) transition, and the 1199G4A SNP (Ser400Asn) that we have shown to cause a functional alteration in P-gp activity. 10, 11 Because significant linkage disequilibrium (LD) exists in ABCB1, we also evaluated the associated risk of ABCB1 haplotypes. [12] [13] [14] Understanding the influence of genetic variability in the intrarenal concentrations of CNIs in post-HCT patients may allow for the a priori identification of patients at high risk of CNI-induced renal dysfunction who would be candidates for non-CNI containing regimens.
Results

Patient characteristics
The demographic characteristics of the study cohort have been described previously. 1 The demographics of the 121 patients for whom DNA was available did not differ significantly from those of the cohort as a whole.
Genotype frequencies
Frequencies of CYP3A5 and ABCB1 genotypes observed in this cohort are displayed in Table 1 . All genotypes were in Hardy-Weinberg equilibrium. The ABCB1 1199G4A SNP was observed with low frequency, but it was comparable to what has been observed in the literature. 13, 15, 16 We observed all three alleles at the 2677 locus; however, the 2677A allele was found with low prevalence and was only observed in heterozygous patients 2677TA or 2677GA.
SNP associations with acute kidney injury
Since trough blood concentrations of CNIs were targeted according to standard clinical guidelines, we decided to focus on the clinical end point of renal injury to evaluate pharmacogenomic associations. AKI was observed in 48 of 121 patients (39.7%). The median day of AKI incidence was day 33 post-HCT (range: day 1-97). We analyzed the associations between the development of AKI and the SNPs in CYP3A5 and ABCB1 in this study population. Table 2 shows the univariate odds ratios (OR) for the risk of AKI for the single genetic predictors. None of the genotypes was statistically associated with AKI in this population. Figure 1 shows the cumulative frequency of AKI by genotype in the first 100 days post-HCT for the 1236C4T, 2677G4T and 3435C4T (patients with 2677A allele were omitted since the number of patients was low). While the OR do not indicate a significant association between ABCB1 genotypes and incidence of AKI, there appears to be non-significant trends toward increased risk of AKI in patients homozygous for 1236TT and 2677TT, especially after day 60 post-HCT. An approximate 17% increase in the incidence of AKI was observed in homozygous 1236TT patients compared to 1236CT and 1236CC patients ( Figure 1a) . A similar nonsignificant trend was also observed with the non-synonymous ABCB1 2677G4T SNP; an approximate 12% increase in the incidence of AKI was observed in homozygous 2677TT patients compared to 2677GT and 2677GG patients (Figure 1b) . However, an associated risk of AKI was not apparent with the ABCB1 3435C4T SNP (Figure 1c ). Although the number of patients with the ABCB1 1199A allele is low, it appeared that heterozygous 1199GA patients have an approximate 20% decrease in the incidence of AKI.
On the basis of power analyses of the differences in risk between genotype groups, we were underpowered to detect a significant association in this retrospective trial.
SNP associations with chronic kidney disease
Among the 66 patients with relevant data in the time period, there were 16 cases of CKD (24.2%); therefore, we were limited in patient numbers for analysis. Table 3 shows the univariate OR of CKD for the single genetic predictors. None of the genotypes was statistically significantly associated with CKD in this population. The OR could not be estimated for the ABCB1 1199G4A SNP since there were no CKD cases in individuals possessing the 1199A allele.
ABCB1 haplotype inference and association with renal disease Significant LD exists between ABCB1 SNPs; 12-14 therefore, we also performed haplotype association analyses. The degree of LD (calculated as r 2 ) between ABCB1 SNPs was estimated in this population. The 1236C4T and 2677G4T/A SNPs were in tight LD (0.72). The 3435C4T SNP was in significant LD with other SNPs, but to a lesser degree; 3435C4T and 2677G4T/A (0.44), and 3435C4T and 1236C4T (0.42). ABCB1 1199G4A showed no LD to other SNPs (o0.05). Next, the haplotype structure in this population was inferred and haplotype frequencies, with their corresponding standard error (7s.e.), were estimated. The three most common haplotypes among the ABCB1 SNPs are 1199G/1236C/2677G/3435C (40.970.9%), 1199G/ 1236T/2677T/3435T (29.970.7%) and 1199G/1236C/ 2677G/3435T (11.870.8%). All other haplotypes inferred in this cohort had a frequency less than 5% and were grouped together for subsequent analyses. Table 4 shows the relationship between ABCB1 haplotypes and the incidence of AKI and CKD post-HCT. There were no associations between the ABCB1 haplotypes and the incidence of AKI or CKD.
Discussion
In this analysis, we did not observe significant pharmacogenomic associations between AKI and CKD and the ABCB1 and CYP3A5 SNPs that regulate protein expression and activity of enzymes and transporters influencing CNI disposition in the kidney. In our cohort of HCT patients, genomic DNA was available for 121 patients who received a myeloablative conditioning regimen before HCT. While the data are suggestive of a relationship between ABCB1 1236C4T, 2677G4T and 1199G4A SNPs and the development of AKI in a myeloablative allogeneic HCT setting, the declining use of myeloablative HCT conditioning regimens makes it unlikely that studies in a larger patient population are feasible.
Renal injury remains a common problem after allogeneic HCT and exposure to CNI-containing immunosuppressive regimens may play a role in the development of disease. We recently showed that systemic cyclosporine levels are not associated with AKI. 2 Therefore, intracellular CNI exposure in kidney tubule cells, mediated by CYP3A5 and P-gp, may be more predictive of renal injury. Since CYP3A5 and P-gp are highly expressed in the kidney, genetic variability in their expression and activity may be critical determinants of intracellular concentrations of CNIs in the kidney tubules; and therefore, may influence CNI-induced renal injury. The primary drug-metabolizing enzymes involved in CNI metabolism are CYP3A4 and CYP3A5 in humans. Tissue expression of CYP3A5 is widespread and it is the major CYP3A isozyme in the kidneys. [17] [18] [19] The major cause of polymorphic CYP3A5 expression is due to the CYP3A5*3 polymorphism. CYP3A5*3 results from a single base substitution within intron-3 (A6986G), which creates an alternative splice site and results in the production of aberrant mRNA and a truncated, non-functional protein. 8, 20 CYP3A5 protein expression in the kidney and CYP3A5 catalytic activity in kidney microsomes are substantially reduced in samples with the CYP3A5*3/*3 genotype. 8, 17 P-gp is expressed in many tissues important for CNI drug disposition including the kidneys. 21 P-gp limits cellular exposure to CNIs by actively effluxing the drugs out of cells. ABCB1 is highly polymorphic and displays considerable LD and several SNPs have been associated with changes in the expression and activity of P-gp. 9 The first ABCB1 polymorphism found to be associated with alterations in P-gp was the synonymous SNP 3435C4T. 16 Subsequently, it was reported that 3435C4T is in LD with two other ABCB1 SNPs; a tri-allelic non-synonymous SNP at nucleotide position 2677, which results in a 2677G4T (Ala893Ser) and a 2677G4A (Ala893Thr) transition, as well as 1236C4T, another synonymous SNP. 13 In addition, we have recently observed a functional alteration in P-gp activity due to another non-synonymous ABCB1 polymorphism, 1199G4A (Ser400Asn). 10, 11 The in vivo significance of ABCB1 polymorphisms has been conflicting as to their functional effect on renal P-gp expression. [22] [23] [24] Since significant linkage exists in the ABCB1 gene, it is important to understand the role of ABCB1 haplotypes in pharmacogenomic association studies. We investigated the LD in our cohort of patients, and while strong LD was observed between SNPs, the degree of LD varied. We found that the 1199G4A SNP was not in LD with other ABCB1 SNPs. The strongest LD was observed between the 1236C4T and 2677G4T/A SNPs. The 3435C4T SNP was also in significant LD with 1236C4T and 2677G4T/A, but to a lesser degree. Because there is a high degree of LD between these three ABCB1 SNPs, and that the degree varies between SNPs, it may be important to evaluate the significance not only of individual SNPs, but also the significance of ABCB1 haplotypes. The three most common haplotypes inferred in this cohort of patients were not associated with a risk of AKI or CKD.
Our study is the first to evaluate the pharmacogenomic association of ABCB1 SNPs with AKI and CKD in HCT patients. While statistical significance was not achieved, several non-significant trends were observed between AKI and three of the ABCB1 SNPs (1199G4A, 1236C4T and 2677G4T). While the number of patients with the 1199A allele is low, there was an observed decreased risk for the development of AKI in patients heterozygous for 1199GA, suggesting that patients with this genotype have a lower exposure to CNIs in kidney tubule cells due to increased P-gp-mediated efflux. This is consistent with previous in vitro studies in which we showed that recombinant cells expressing the 1199A variant showed increased P-gp-mediated efflux of anticancer agents and HIV protease inhibitors. 10, 11 Analysis of the impact of the 1199G4A SNP is not complicated by linkage to other ABCB1 SNPs. An increased risk of AKI was observed in patients homozygous for either 1236TT or 2677TT. However, we did not observe a trend in incidence of AKI for the 3435C4T SNP. The discordance between these observed results may be due to the stronger degree of LD observed between 1236C4T and 2677G4T compared to the LD of either SNP with 3435C4T in this cohort of patients. A synonymous SNP would not be Represents the total frequency of the remaining haplotypes. s.e. not calculated since remaining haplotypes were grouped for analysis. Abbreviations: AKI, acute kidney injury; CI, confidence interval; CKD, chronic kidney disease; OR, odds ratio.
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expected to alter protein function; however, a recent study has shown that the silent 3435C4T SNP alters substrate specificity. 25 While we did not observe a trend with 3435C4T, the other 1236C4T synonymous SNP in our study may influence the incidence of AKI. The observed trend towards an increased risk of AKI with the 1236TT and 2677TT genotypes suggests that patients expressing these genotypes have a higher exposure to CNIs in the kidney tubule cells due to decreased P-gp-mediated efflux.
In the solid organ transplant setting, studies evaluating the effect of ABCB1 polymorphisms on CNI dose requirements, blood concentrations and CNI-induced renal injury have produced variable results. 26, 27 Liver transplant patients receiving CNI-containing immunosuppressive regimens who were homozygous for 2677TT had a reduced risk of renal injury, but no association was observed with the 3435C4T SNP. 28 In contrast, a study in renal transplant patients receiving CNIs found that 3435TT donor genotypes were associated with an increased risk of renal injury, while no association was observed with the 2677G4T SNP. 29 Therefore, the influence of ABCB1 polymorphisms on the risk of CNI-induced renal injury in solid organ transplant patients is conflicting, and our data in HCT patients also are not consistent with these results. Several confounding factors may play a role in these discordant results such as disease states, concomitant medication (particularly amphotericin, used in 38 patients in our cohort), environmental factors and differences in CNI regimens. In addition, other genetic factors may play a role in CNI-induced kidney disease. We have shown that several genes in the immune and inflammatory pathways are associated with the development of AKI post-HCT. 30 In conclusion, there do not appear to be pharmacogenomic associations between polymorphisms and haplotypes in the CYP3A5 and ABCB1 genes and the development of AKI or CKD in patients following myeloablative HCT. Therefore, tailoring the CNI dose based on these genotypes is unlikely to lower significantly the risk of AKI or CKD. Alternative strategies for identifying risk factors for kidney injury in patients undergoing myeloablative HCT should be pursued given the necessity of CNI as GVHD prophylaxis and the frequent onset of renal dysfunction post-HCT.
Materials and methods
Study population
One hundred forty-seven patients with hematologic malignancies who were undergoing allogeneic transplantation following a conditioning regimen of cyclophosphamide plus total body irradiation were enrolled between April 1997 and January 2000 at the Fred Hutchinson Cancer Research Center (Seattle, WA, USA). All signed informed consent was approved by the Institutional Review Board of the Fred Hutchinson Cancer Research Center. The clinical risk factors for SOS and AKI in this cohort have been reported previously. 1, 2 Seven days before the infusion of stem cells, cyclophosphamide was infused through a central venous access catheter for over 1-2 h at a dose of 60 mg/kg body weight. On the following day, a second infusion of the same dose of cyclophosphamide was given. The pharmacokinetics and pharmacodynamics of cyclophosphamide and metabolites in this cohort of patients has been published. 1 After a day of rest, total body irradiation (9-14.2 Gy) was given daily for three or four subsequent days in hyperfractionated doses from opposing cobalt sources. The kidneys were not shielded. Prophylaxis regimens against GVHD included a CNI, cyclosporine or tacrolimus and methotrexate in the majority of patients, or variations on the above, including prednisolone and BC3; BC3 is a murine antibody specific for human CD3.
1,2 CNIs were targeted to trough concentrations according to standard practice guidelines or individual protocol specifications; cyclosporine trough levels are generally targeted to between 150 and 450 ng/ml and tacrolimus trough levels are generally targeted to between 5 and 15 ng/ml. Donor hematopoietic cells were infused on day 'zero'; by convention, all subsequent days are numbered from this day.
Preparation of DNA B-lymphoblastoid cells were collected from patients before HCT and were used to establish permanent growing lymphoblastoid cell lines using an Epstein-Barr virus transformation method. 31 Genomic DNA was extracted using a QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA, USA) from immortalized B-lymphoblastoid cell lines as described previously. 32 Genomic DNA was available for 121 of the 147 patients enrolled in the study. The quality of DNA samples was tested by spectrophotometric analysis at 260 and 280 nm.
Determination of CYP3A5 and ABCB1 genotypes Genotyping was performed at the DNA Sequencing and Gene Analysis Center (Department of Pharmaceutics, University of Washington, Seattle, WA, USA). Patients were genotyped for SNPs in the CYP3A5 and ABCB1 genes using allelic-discrimination TaqMan SNP Genotyping Assays (Applied Biosystems, Foster City, CA, USA). The reference SNP ID number for these assays were CYP3A5*14*3 (rs776746) and ABCB1 1199G4A (rs2229109), 1236C4T (rs1128503) and 3435C4T (rs1045642) SNPs. The tri-allelic ABCB1 2677G4T/A SNP was determined based on a custommade assay that has been described previously: forward primer (5 0 -GTAAGCAGTAGGGAGTAACAAAATAACACT-3 0 ), reverse primer (5 0 -GACAAGCACTGAAAGATAAGAAAGAA CT-3 0 ), 2677G allele probe (5 0 -CCTTCCCAGCACCT-3 0 ), 2677T allele probe: (5 0 -CTTCCCAGAACCTT-3 0 ) and 2677A allele probe (5 0 -CTTCCCAGTACCTTC-3 0 ). 33 The cycling conditions for PCR amplification were one cycle at 951C for 10 min, followed by 40 cycles of 951C for 15 s, and 601C for 1 min in a reaction volume of 10 ml containing 1 ml of genomic DNA (B25-100 ng), and 1 Â final concentrations of TaqMan Universal PCR Master Mix and TaqMan SNP Genotyping Assay primers and probes (Applied Biosystems). The allelic discrimination was determined in a post-PCR analysis on a 7900HT Fast Real-Time PCR System (Applied Biosystems) with allele-specific probes for the common and variant SNPs (FAM and VIC, respectively) by Sequence Detection Systems version 2.2.1 (Applied Biosystems). Internal controls of sequence-verified genotypes were included for each assay.
Definitions of kidney injury AKI was defined as a doubling of baseline serum creatinine within the first 100 days after transplant. 2, 34 Baseline serum creatinine was the value obtained before the start of myeloablative conditioning therapy. AKI was assessed in all 121 patients.
CKD was defined as at least one value of glomerular filtration rate (GFR) o60 ml/min/m 2 between 6 and 18 months post-HCT (days 180-540). 35 GFR was calculated using the modification of diet in renal disease equation for adults and the Schwartz formula for children. 36, 37 Because of difficulties in acquiring patient samples on later days post-HCT, only 66 of the 121 patients in this cohort had GFR measurements in the time period of interest. Therefore, CKD was assessed only in these 66 patients.
Statistical analysis
We analyzed the associations between the incidences of AKI and CKD with genetic polymorphisms in CYP3A5 and ABCB1 in this study population, as well as the inferred haplotypes of ABCB1. OR for the development of AKI and CKD were calculated using logistic regression models with 95% confidence intervals. Analyses were performed using SAS statistical software (Cary, NC, USA). The following factors were considered as potential confounders: age at transplant, sex, gain in weight from baseline to the end of exposure period, baseline serum creatinine, amphotericin use and the incidence of moderate to severe SOS based on our previous analysis. 2 Cumulative incidence plots of the probability of AKI over the first 100 days post-HCT by genotype was estimated. 38 Death without AKI was treated as a competing risk.
LD between ABCB1 SNPs was estimated based on the r 
